CTEC Global X CleanTech ETF

HAYWARD, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Cholestech Corporation (NASDAQ:CTEC), a leading manufacturer of point of care testing devices, today announced that it is partnering with AstraZeneca (NYSE:AZN), a leading pharmaceutical company. Cholestech is providing a high sensitivity C-Reactive Protein (hs-CRP) test for the Cholestech LDX(R) System to rapidly pre-screen patients for eligibility to participate in a global multi-site clinical study, sponsored by AstraZeneca. "We know that individuals with increased blood levels of hs-CRP are at high risk for heart attack and stroke, even if they have normal cholesterol levels," said Dr. Paul Ridker, a cardiologist at the Brigham and Women's Hospital in Boston and Principal Investigator for the AstraZeneca clinical trial. The AstraZeneca clinical trial is designed to investigate the effect of a statin in the primary prevention of cardiovascular events in patients with normal to low cholesterol levels but elevated hs-CRP. C-Reactive protein (CRP) is a systemic marker of inflammation. The hs-CRP test is used to detect low-level increases of CRP in apparently healthy individuals. These increases are due to more subtle forms of inflammation, such as inflammation in the blood vessels, and cannot be detected using conventional CRP assays. An expanding body of research indicates that CRP may play a direct, active inflammatory role in blood vessels, leading to the development of atherosclerosis. Atherosclerosis is now considered an inflammatory disorder of the blood vessels similar to the way arthritis is an inflammatory disorder of the bones and joints. "We are pleased to partner with AstraZeneca to make the LDX System widely available to AstraZeneca clinical trial investigators, giving them a tool to quickly and easily measure both hs-CRP and lipids," said Warren E. Pinckert II, president and CEO of Cholestech. The Cholestech hs-CRP test can be performed on the LDX point of care system, which generates comprehensive, lab accurate results in minutes using a small fingerstick blood sample. The LDX System is already the leading physician office based system used to measure and monitor cholesterol, enabling physicians to review test results and provide counsel and treatment options all in the same office visit. The LDX System has been certified by the Cholesterol Reference Method Laboratory Network (CRMLN). This certification validates that the system consistently meets the gold standard for accuracy and reproducibility developed by the Centers for Disease Control for the measurement of total cholesterol and HDL cholesterol. About AstraZeneca AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of over $21.4 billion and leading positions in sales of gastrointestinal, cardiovascular, respiratory, oncology and neuroscience products. In the United States, AstraZeneca is a $9.6 billion healthcare business with more than 12,000 employees. AstraZeneca is listed in the Dow Joes Sustainability Index (Global) as well as the FTSE4 Good Index. For more information about AstraZeneca, please visit: http://www.astrazeneca-us.com/. About Cholestech Cholestech is committed to enabling people to lead longer, healthier and more active lives. Cholestech provides easy to use, accessible diagnostic tools and information to healthcare practitioners in over 35 countries around the world. Cholestech offers efficient and economic diagnostic testing for cholesterol and related lipids, blood glucose and A1C, and liver function at the point of care. Healthcare providers can use the CLIA-waived Cholestech LDX(R) and GDX(TM) Systems to initiate and monitor the progress of patient therapy. By providing effective disease management solutions, Cholestech's goal is to be a leading provider of diagnostic tools and information for immediate risk assessment and therapeutic monitoring of heart disease and diabetes. Cholestech LDX(R) is a registered trademark and Cholestech GDX(TM) is a trademark of Cholestech Corporation. All other trademarks mentioned in this document are the property of their respective owners. For more information about Cholestech, please visit: http://www.cholestech.com/. DATASOURCE: Cholestech Corporation CONTACT: Warren E. Pinckert II, President and Chief Executive Officer of Cholestech Corporation, +1-510-732-7200, or ; or Emily Denney, Associate Director, Public Relations of AstraZeneca, +1-302-885-3451, or Web site: http://www.astrazeneca-us.com/ Web site: http://www.cholestech.com/

Copyright